Crescita TherapeuticsTSX:CTX 20 OCF Margin % is 2.52% as of Mar. 2026, which is 581% above its 10-year median of 0.37. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 964 Drug Manufacturers companies, Crescita Therapeutics ranks worse than 55.19% on this metric.
The historical rank and industry rank for Crescita Therapeutics's OCF Margin % or its related term are showing as below:
TSX:CTX'
s OCF Margin % Range Over the Past 10 Years
Min: -530.17 Med: 0.37 Max: 35.86
Current: 7.44
During the past 12 years, the highest OCF Margin % of Crescita Therapeutics was 35.86%. The lowest was -530.17%. And the median was 0.37%.
TSX:CTX's OCF Margin % is ranked worse than 55.19% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs TSX:CTX: 7.44
Crescita Therapeutics OCF Margin % Related Terms
Crescita Therapeutics OCF Margin % Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a OCF Margin % of 2.52% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Crescita Therapeutics and its competitors. This is 581% above median its historical median of 0.37. According to the industry distribution chart, Crescita Therapeutics ranks #532 out of 964 companies in the Drug Manufacturers industry, placing it in the top 55.2%.
Is Crescita Therapeutics' OCF Margin % too high?
Crescita Therapeutics' current OCF Margin % of 2.52% is 581% above median its 10-year median of 0.37. The Drug Manufacturers industry median OCF Margin % is 10.04. Crescita Therapeutics' value of 2.52% is 74.9% below this industry median. Based on the distribution chart, Crescita Therapeutics ranks #532 out of 964 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #532 out of 964 companies for OCF Margin %. This places Crescita Therapeutics in the lower half of its industry. The industry median OCF Margin % is 10.04. Crescita Therapeutics' value of 2.52% is 74.9% below this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 10.04, Crescita Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current OCF Margin % of 2.52% is 74.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Crescita Therapeutics and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current OCF Margin % is 2.52%, which is 581% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current OCF Margin % is 2.52%, which is 581% above median its 10-year median of 0.37 and 74.9% below the Drug Manufacturers industry median of 10.04. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current OCF Margin % is 2.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued.
The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68.
GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:CTX:
OCF Margin %: 2.52% (581% above median its 10-year median of 0.37)
GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
Industry Position: 74.9% below the Drug Manufacturers median (#532 of 964)
No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
